Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary Tumor Resection for Stage IV NSCLC After Afatinib
NCT05215548Phase 2Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2021
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: 2-year Progression-Free Survival Rate. Started Sep 2021; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05215548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215548.